Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas
Previous studies have demonstrated the feasibility of using apathogenic clostridia as a promising strategy for hypoxia-specific tumour targeting. The present study shows that the use of the vascular targeting compound combretastatin A-4 phosphate could significantly (P<0.001) increase the number...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
Oxford, UK: Blackwell Publishing Ltd ; 2001 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
Online-Ressource |
|---|
| Reproduktion: |
2006 ; Blackwell Publishing Journal Backfiles 1879-2005 |
|---|---|
| Übergeordnetes Werk: |
In: FEMS immunology and medical microbiology - Federation of European Microbiological Societies ; GKD-ID: 114439X, Oxford [u.a.] : Wiley-Blackwell, 1993, 30(2001), 1, Seite 0 |
| Übergeordnetes Werk: |
volume:30 ; year:2001 ; number:1 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1111/j.1574-695X.2001.tb01547.x |
|---|
| Katalog-ID: |
NLEJ242928552 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ242928552 | ||
| 003 | DE-627 | ||
| 005 | 20230505190918.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 120427s2001 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/j.1574-695X.2001.tb01547.x |2 doi | |
| 035 | |a (DE-627)NLEJ242928552 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 245 | 1 | 0 | |a Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas |
| 264 | 1 | |a Oxford, UK |b Blackwell Publishing Ltd |c 2001 | |
| 300 | |a Online-Ressource | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Previous studies have demonstrated the feasibility of using apathogenic clostridia as a promising strategy for hypoxia-specific tumour targeting. The present study shows that the use of the vascular targeting compound combretastatin A-4 phosphate could significantly (P<0.001) increase the number of Clostridium vegetative cells in rat rhabdomyosarcomas with sizes between 0.2 cm2 and 3 cm2. Furthermore, this study showed that administration of metronidazole for a 9-day period was sufficient to eliminate systemically administered Clostridium from the tumour. Moreover, previous Clostridium spore administration did not effect tumour colonisation, regardless of the immune response status of the host. | ||
| 533 | |d 2006 |f Blackwell Publishing Journal Backfiles 1879-2005 |7 |2006|||||||||| | ||
| 650 | 4 | |a Anti-cancer treatment | |
| 700 | 1 | |a Theys, Jan |4 oth | |
| 700 | 1 | |a Landuyt, Willy |4 oth | |
| 700 | 1 | |a Nuyts, Sandra |4 oth | |
| 700 | 1 | |a Mellaert, Lieve |4 oth | |
| 700 | 1 | |a Bosmans, Eugène |4 oth | |
| 700 | 1 | |a Rijnders, Alex |4 oth | |
| 700 | 1 | |a Bogaert, Walter |4 oth | |
| 700 | 1 | |a Oosterom, Allan |4 oth | |
| 700 | 1 | |a Anné, Jozef |4 oth | |
| 700 | 1 | |a Lambin, Philippe |4 oth | |
| 773 | 0 | 8 | |i In |a Federation of European Microbiological Societies ; GKD-ID: 114439X |t FEMS immunology and medical microbiology |d Oxford [u.a.] : Wiley-Blackwell, 1993 |g 30(2001), 1, Seite 0 |h Online-Ressource |w (DE-627)NLEJ243926014 |w (DE-600)1500464-8 |x 1574-695X |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2001 |g number:1 |g pages:0 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/j.1574-695X.2001.tb01547.x |q text/html |x Verlag |z Deutschlandweit zugänglich |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-DJB | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2001 |e 1 |h 0 | ||
| matchkey_str |
article:1574695X:2001----::mrvmnocotiimuoragtnvcosvlaei |
|---|---|
| hierarchy_sort_str |
2001 |
| publishDate |
2001 |
| allfields |
10.1111/j.1574-695X.2001.tb01547.x doi (DE-627)NLEJ242928552 DE-627 ger DE-627 rakwb Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas Oxford, UK Blackwell Publishing Ltd 2001 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Previous studies have demonstrated the feasibility of using apathogenic clostridia as a promising strategy for hypoxia-specific tumour targeting. The present study shows that the use of the vascular targeting compound combretastatin A-4 phosphate could significantly (P<0.001) increase the number of Clostridium vegetative cells in rat rhabdomyosarcomas with sizes between 0.2 cm2 and 3 cm2. Furthermore, this study showed that administration of metronidazole for a 9-day period was sufficient to eliminate systemically administered Clostridium from the tumour. Moreover, previous Clostridium spore administration did not effect tumour colonisation, regardless of the immune response status of the host. 2006 Blackwell Publishing Journal Backfiles 1879-2005 |2006|||||||||| Anti-cancer treatment Theys, Jan oth Landuyt, Willy oth Nuyts, Sandra oth Mellaert, Lieve oth Bosmans, Eugène oth Rijnders, Alex oth Bogaert, Walter oth Oosterom, Allan oth Anné, Jozef oth Lambin, Philippe oth In Federation of European Microbiological Societies ; GKD-ID: 114439X FEMS immunology and medical microbiology Oxford [u.a.] : Wiley-Blackwell, 1993 30(2001), 1, Seite 0 Online-Ressource (DE-627)NLEJ243926014 (DE-600)1500464-8 1574-695X nnns volume:30 year:2001 number:1 pages:0 http://dx.doi.org/10.1111/j.1574-695X.2001.tb01547.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 30 2001 1 0 |
| spelling |
10.1111/j.1574-695X.2001.tb01547.x doi (DE-627)NLEJ242928552 DE-627 ger DE-627 rakwb Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas Oxford, UK Blackwell Publishing Ltd 2001 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Previous studies have demonstrated the feasibility of using apathogenic clostridia as a promising strategy for hypoxia-specific tumour targeting. The present study shows that the use of the vascular targeting compound combretastatin A-4 phosphate could significantly (P<0.001) increase the number of Clostridium vegetative cells in rat rhabdomyosarcomas with sizes between 0.2 cm2 and 3 cm2. Furthermore, this study showed that administration of metronidazole for a 9-day period was sufficient to eliminate systemically administered Clostridium from the tumour. Moreover, previous Clostridium spore administration did not effect tumour colonisation, regardless of the immune response status of the host. 2006 Blackwell Publishing Journal Backfiles 1879-2005 |2006|||||||||| Anti-cancer treatment Theys, Jan oth Landuyt, Willy oth Nuyts, Sandra oth Mellaert, Lieve oth Bosmans, Eugène oth Rijnders, Alex oth Bogaert, Walter oth Oosterom, Allan oth Anné, Jozef oth Lambin, Philippe oth In Federation of European Microbiological Societies ; GKD-ID: 114439X FEMS immunology and medical microbiology Oxford [u.a.] : Wiley-Blackwell, 1993 30(2001), 1, Seite 0 Online-Ressource (DE-627)NLEJ243926014 (DE-600)1500464-8 1574-695X nnns volume:30 year:2001 number:1 pages:0 http://dx.doi.org/10.1111/j.1574-695X.2001.tb01547.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 30 2001 1 0 |
| allfields_unstemmed |
10.1111/j.1574-695X.2001.tb01547.x doi (DE-627)NLEJ242928552 DE-627 ger DE-627 rakwb Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas Oxford, UK Blackwell Publishing Ltd 2001 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Previous studies have demonstrated the feasibility of using apathogenic clostridia as a promising strategy for hypoxia-specific tumour targeting. The present study shows that the use of the vascular targeting compound combretastatin A-4 phosphate could significantly (P<0.001) increase the number of Clostridium vegetative cells in rat rhabdomyosarcomas with sizes between 0.2 cm2 and 3 cm2. Furthermore, this study showed that administration of metronidazole for a 9-day period was sufficient to eliminate systemically administered Clostridium from the tumour. Moreover, previous Clostridium spore administration did not effect tumour colonisation, regardless of the immune response status of the host. 2006 Blackwell Publishing Journal Backfiles 1879-2005 |2006|||||||||| Anti-cancer treatment Theys, Jan oth Landuyt, Willy oth Nuyts, Sandra oth Mellaert, Lieve oth Bosmans, Eugène oth Rijnders, Alex oth Bogaert, Walter oth Oosterom, Allan oth Anné, Jozef oth Lambin, Philippe oth In Federation of European Microbiological Societies ; GKD-ID: 114439X FEMS immunology and medical microbiology Oxford [u.a.] : Wiley-Blackwell, 1993 30(2001), 1, Seite 0 Online-Ressource (DE-627)NLEJ243926014 (DE-600)1500464-8 1574-695X nnns volume:30 year:2001 number:1 pages:0 http://dx.doi.org/10.1111/j.1574-695X.2001.tb01547.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 30 2001 1 0 |
| allfieldsGer |
10.1111/j.1574-695X.2001.tb01547.x doi (DE-627)NLEJ242928552 DE-627 ger DE-627 rakwb Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas Oxford, UK Blackwell Publishing Ltd 2001 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Previous studies have demonstrated the feasibility of using apathogenic clostridia as a promising strategy for hypoxia-specific tumour targeting. The present study shows that the use of the vascular targeting compound combretastatin A-4 phosphate could significantly (P<0.001) increase the number of Clostridium vegetative cells in rat rhabdomyosarcomas with sizes between 0.2 cm2 and 3 cm2. Furthermore, this study showed that administration of metronidazole for a 9-day period was sufficient to eliminate systemically administered Clostridium from the tumour. Moreover, previous Clostridium spore administration did not effect tumour colonisation, regardless of the immune response status of the host. 2006 Blackwell Publishing Journal Backfiles 1879-2005 |2006|||||||||| Anti-cancer treatment Theys, Jan oth Landuyt, Willy oth Nuyts, Sandra oth Mellaert, Lieve oth Bosmans, Eugène oth Rijnders, Alex oth Bogaert, Walter oth Oosterom, Allan oth Anné, Jozef oth Lambin, Philippe oth In Federation of European Microbiological Societies ; GKD-ID: 114439X FEMS immunology and medical microbiology Oxford [u.a.] : Wiley-Blackwell, 1993 30(2001), 1, Seite 0 Online-Ressource (DE-627)NLEJ243926014 (DE-600)1500464-8 1574-695X nnns volume:30 year:2001 number:1 pages:0 http://dx.doi.org/10.1111/j.1574-695X.2001.tb01547.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 30 2001 1 0 |
| allfieldsSound |
10.1111/j.1574-695X.2001.tb01547.x doi (DE-627)NLEJ242928552 DE-627 ger DE-627 rakwb Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas Oxford, UK Blackwell Publishing Ltd 2001 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Previous studies have demonstrated the feasibility of using apathogenic clostridia as a promising strategy for hypoxia-specific tumour targeting. The present study shows that the use of the vascular targeting compound combretastatin A-4 phosphate could significantly (P<0.001) increase the number of Clostridium vegetative cells in rat rhabdomyosarcomas with sizes between 0.2 cm2 and 3 cm2. Furthermore, this study showed that administration of metronidazole for a 9-day period was sufficient to eliminate systemically administered Clostridium from the tumour. Moreover, previous Clostridium spore administration did not effect tumour colonisation, regardless of the immune response status of the host. 2006 Blackwell Publishing Journal Backfiles 1879-2005 |2006|||||||||| Anti-cancer treatment Theys, Jan oth Landuyt, Willy oth Nuyts, Sandra oth Mellaert, Lieve oth Bosmans, Eugène oth Rijnders, Alex oth Bogaert, Walter oth Oosterom, Allan oth Anné, Jozef oth Lambin, Philippe oth In Federation of European Microbiological Societies ; GKD-ID: 114439X FEMS immunology and medical microbiology Oxford [u.a.] : Wiley-Blackwell, 1993 30(2001), 1, Seite 0 Online-Ressource (DE-627)NLEJ243926014 (DE-600)1500464-8 1574-695X nnns volume:30 year:2001 number:1 pages:0 http://dx.doi.org/10.1111/j.1574-695X.2001.tb01547.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 30 2001 1 0 |
| source |
In FEMS immunology and medical microbiology 30(2001), 1, Seite 0 volume:30 year:2001 number:1 pages:0 |
| sourceStr |
In FEMS immunology and medical microbiology 30(2001), 1, Seite 0 volume:30 year:2001 number:1 pages:0 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Anti-cancer treatment |
| isfreeaccess_bool |
false |
| container_title |
FEMS immunology and medical microbiology |
| authorswithroles_txt_mv |
Theys, Jan @@oth@@ Landuyt, Willy @@oth@@ Nuyts, Sandra @@oth@@ Mellaert, Lieve @@oth@@ Bosmans, Eugène @@oth@@ Rijnders, Alex @@oth@@ Bogaert, Walter @@oth@@ Oosterom, Allan @@oth@@ Anné, Jozef @@oth@@ Lambin, Philippe @@oth@@ |
| publishDateDaySort_date |
2001-01-01T00:00:00Z |
| hierarchy_top_id |
NLEJ243926014 |
| id |
NLEJ242928552 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242928552</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505190918.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2001 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1111/j.1574-695X.2001.tb01547.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242928552</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Publishing Ltd</subfield><subfield code="c">2001</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Previous studies have demonstrated the feasibility of using apathogenic clostridia as a promising strategy for hypoxia-specific tumour targeting. The present study shows that the use of the vascular targeting compound combretastatin A-4 phosphate could significantly (P<0.001) increase the number of Clostridium vegetative cells in rat rhabdomyosarcomas with sizes between 0.2 cm2 and 3 cm2. Furthermore, this study showed that administration of metronidazole for a 9-day period was sufficient to eliminate systemically administered Clostridium from the tumour. Moreover, previous Clostridium spore administration did not effect tumour colonisation, regardless of the immune response status of the host.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2006</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2006||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Anti-cancer treatment</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Theys, Jan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Landuyt, Willy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nuyts, Sandra</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mellaert, Lieve</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bosmans, Eugène</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rijnders, Alex</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bogaert, Walter</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Oosterom, Allan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Anné, Jozef</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lambin, Philippe</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="a">Federation of European Microbiological Societies ; GKD-ID: 114439X</subfield><subfield code="t">FEMS immunology and medical microbiology</subfield><subfield code="d">Oxford [u.a.] : Wiley-Blackwell, 1993</subfield><subfield code="g">30(2001), 1, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243926014</subfield><subfield code="w">(DE-600)1500464-8</subfield><subfield code="x">1574-695X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:30</subfield><subfield code="g">year:2001</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1111/j.1574-695X.2001.tb01547.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">30</subfield><subfield code="j">2001</subfield><subfield code="e">1</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| series2 |
Blackwell Publishing Journal Backfiles 1879-2005 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ243926014 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| publishPlace |
Oxford, UK |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1574-695X |
| topic_title |
Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas Anti-cancer treatment |
| publisher |
Blackwell Publishing Ltd |
| publisherStr |
Blackwell Publishing Ltd |
| topic |
misc Anti-cancer treatment |
| spellingShingle |
misc Anti-cancer treatment Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas |
| topic_unstemmed |
misc Anti-cancer treatment |
| topic_browse |
misc Anti-cancer treatment |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
j t jt w l wl s n sn l m lm e b eb a r ar w b wb a o ao j a ja p l pl |
| hierarchy_parent_title |
FEMS immunology and medical microbiology |
| hierarchy_parent_id |
NLEJ243926014 |
| hierarchy_top_title |
FEMS immunology and medical microbiology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ243926014 (DE-600)1500464-8 |
| title |
Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas |
| ctrlnum |
(DE-627)NLEJ242928552 |
| title_full |
Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas |
| journal |
FEMS immunology and medical microbiology |
| journalStr |
FEMS immunology and medical microbiology |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2001 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| container_volume |
30 |
| physical |
Online-Ressource |
| format_se |
Elektronische Aufsätze |
| doi_str_mv |
10.1111/j.1574-695X.2001.tb01547.x |
| title_sort |
improvement of clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas |
| title_auth |
Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas |
| abstract |
Previous studies have demonstrated the feasibility of using apathogenic clostridia as a promising strategy for hypoxia-specific tumour targeting. The present study shows that the use of the vascular targeting compound combretastatin A-4 phosphate could significantly (P<0.001) increase the number of Clostridium vegetative cells in rat rhabdomyosarcomas with sizes between 0.2 cm2 and 3 cm2. Furthermore, this study showed that administration of metronidazole for a 9-day period was sufficient to eliminate systemically administered Clostridium from the tumour. Moreover, previous Clostridium spore administration did not effect tumour colonisation, regardless of the immune response status of the host. |
| abstractGer |
Previous studies have demonstrated the feasibility of using apathogenic clostridia as a promising strategy for hypoxia-specific tumour targeting. The present study shows that the use of the vascular targeting compound combretastatin A-4 phosphate could significantly (P<0.001) increase the number of Clostridium vegetative cells in rat rhabdomyosarcomas with sizes between 0.2 cm2 and 3 cm2. Furthermore, this study showed that administration of metronidazole for a 9-day period was sufficient to eliminate systemically administered Clostridium from the tumour. Moreover, previous Clostridium spore administration did not effect tumour colonisation, regardless of the immune response status of the host. |
| abstract_unstemmed |
Previous studies have demonstrated the feasibility of using apathogenic clostridia as a promising strategy for hypoxia-specific tumour targeting. The present study shows that the use of the vascular targeting compound combretastatin A-4 phosphate could significantly (P<0.001) increase the number of Clostridium vegetative cells in rat rhabdomyosarcomas with sizes between 0.2 cm2 and 3 cm2. Furthermore, this study showed that administration of metronidazole for a 9-day period was sufficient to eliminate systemically administered Clostridium from the tumour. Moreover, previous Clostridium spore administration did not effect tumour colonisation, regardless of the immune response status of the host. |
| collection_details |
GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE |
| container_issue |
1 |
| title_short |
Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas |
| url |
http://dx.doi.org/10.1111/j.1574-695X.2001.tb01547.x |
| remote_bool |
true |
| author2 |
Theys, Jan Landuyt, Willy Nuyts, Sandra Mellaert, Lieve Bosmans, Eugène Rijnders, Alex Bogaert, Walter Oosterom, Allan Anné, Jozef Lambin, Philippe |
| author2Str |
Theys, Jan Landuyt, Willy Nuyts, Sandra Mellaert, Lieve Bosmans, Eugène Rijnders, Alex Bogaert, Walter Oosterom, Allan Anné, Jozef Lambin, Philippe |
| ppnlink |
NLEJ243926014 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1111/j.1574-695X.2001.tb01547.x |
| up_date |
2024-07-06T03:42:24.959Z |
| _version_ |
1803799594227728384 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242928552</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505190918.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2001 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1111/j.1574-695X.2001.tb01547.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242928552</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Publishing Ltd</subfield><subfield code="c">2001</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Previous studies have demonstrated the feasibility of using apathogenic clostridia as a promising strategy for hypoxia-specific tumour targeting. The present study shows that the use of the vascular targeting compound combretastatin A-4 phosphate could significantly (P<0.001) increase the number of Clostridium vegetative cells in rat rhabdomyosarcomas with sizes between 0.2 cm2 and 3 cm2. Furthermore, this study showed that administration of metronidazole for a 9-day period was sufficient to eliminate systemically administered Clostridium from the tumour. Moreover, previous Clostridium spore administration did not effect tumour colonisation, regardless of the immune response status of the host.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2006</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2006||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Anti-cancer treatment</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Theys, Jan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Landuyt, Willy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nuyts, Sandra</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mellaert, Lieve</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bosmans, Eugène</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rijnders, Alex</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bogaert, Walter</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Oosterom, Allan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Anné, Jozef</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lambin, Philippe</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="a">Federation of European Microbiological Societies ; GKD-ID: 114439X</subfield><subfield code="t">FEMS immunology and medical microbiology</subfield><subfield code="d">Oxford [u.a.] : Wiley-Blackwell, 1993</subfield><subfield code="g">30(2001), 1, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243926014</subfield><subfield code="w">(DE-600)1500464-8</subfield><subfield code="x">1574-695X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:30</subfield><subfield code="g">year:2001</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1111/j.1574-695X.2001.tb01547.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">30</subfield><subfield code="j">2001</subfield><subfield code="e">1</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.400567 |